Not only onconeuronal antibodies, but also neuronal surface antibodies may point to an underlying malignancy (for example: NMDAR antibodies to teratoma, in up to ~40%, CASPR2 antibodies, to thymoma in ~20%–50%; DPPX antibodies to B cell malignancies in up to ~10%; GlyR antibodies to thymoma in ~10%; DNER antibodies to Hodgkin's lymphoma in ~90%).18 Here, CNTNAP2 is linked to thymoma.